Amgen drug Kyprolis gets another FDA approval
Amgen scored another victory for its breakthrough multiple myeloma drug on Jan. 21. The Thousand Oaks-based biotech giant hit it big when the Food and Drug Administration approved revolutionary multiple myeloma drug Kyprolis for treatments with Kyprolis in combination with another drug. The FDA also approved Kyprolis to treat patients on its own for those Read More →
Shire buying Conejo Valley’s Baxalta
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen suffers setback as patent office refuses to review competitor’s drug
The U.S. Patent and Trademark Office handed Amgen a potential setback Jan. 14 when it declined to review two patent expiration dates on a competitor’s drug. In June, Thousand Oaks-based biotech giant Amgen asked the agency to review two formulation patents for Humira, made by Chicago-based competitor AbbVie, arguing that the patents should not have Read More →
Shire acquiring Baxalta for $32 billion
Shire PLC sweetened the pot and Baxalta Inc. investors took the bait in a deal announced early Jan. 11. Dublin-based Shire announced a $30 billion bid for Deefield, Ill.-based Baxalta on Aug. 4. On Jan. 11, the companies announced Shire will acquire Baxalta for $32 billion. Baxalta employs about 2,000 people in Thousand Oaks and Read More →
Sientra implants could be back on the market in weeks
Sientra made three major announcements on Jan. 7: It is not yet resuming production at its factory in Rio de Janeiro, it is looking for a new manufacturer of its implants and the existing inventory could be back on the market within weeks. On Jan. 8, the British Medicines and Healthcare Products Regulatory Agency also Read More →
Surgeons clamor for Sientra implants
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Avoiding ER with Pre-R
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
